« How it happened - Motley Fool | Main | US FDA seeks more study of diabetes drug heart risk - guardian.co.uk »
Gentium Reports Second Quarter Financial Results; Provides Phase ... MarketWatch - The increase is mainly attributable to the reimbursement of certain costs incurred in the Company's Phase III clinical trial of Defibrotide to treat Severe ... |
TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a00e54ed2f1208833010536aac783970c
Listed below are links to weblogs that reference Gentium Reports Second Quarter Financial Results; Provides Phase ... - MarketWatch:
This is only a preview. Your comment has not yet been posted.
As a final step before posting your comment, enter the letters and numbers you see in the image below. This prevents automated programs from posting comments.
Having trouble reading this image? View an alternate.
Comments